Big Pharma

Showing of 1 - 20 from 16 results
Big Pharma - Total results - 16
New drug discovered that helps treat delusions in patients suffering from dementia
science

New drug discovered that helps treat delusions in patients suffering from dementia

The drugs comes with a warning label and the cost could be an issue for patients are it costs about $3,000 a month.

GSK to access DNA data from millions by partnering with Google-funded 23andMe
science

GSK to access DNA data from millions by partnering with Google-funded 23andMe

With more than 5 million customers, 23andMe has a trove of information about the links between genes and disease.

Clinical testing of drugs on dogs is a cruel practice, doesn't add value or provide data that is applicable to humans
India

Clinical testing of drugs on dogs is a cruel practice, doesn't add value or provide data that is applicable to humans

The primary objection to the specific use of dogs in testing is thus simple — the data derived from dogs is not predictive enough to be applied to the case of humans

Why Narendra Modi’s US visits make the sick and poor in India anxious
World

Why Narendra Modi’s US visits make the sick and poor in India anxious

The fear is that if Narendra Modi capitulates to US pressure on India’s Intellectual Property Rights (IPR) regime, which it has been overtly and covertly exerting for years, it will make many lifesaving drugs unaffordable

World Cancer Day: Debate on affordable drugs must focus on life or death for millions
India

World Cancer Day: Debate on affordable drugs must focus on life or death for millions

On World Cancer Day, here is arithmetic to show that big pharma's justification for high prices of life-saving drugs is not the complete truth.

Breast cancer drugs: Is UPA succumbing to US pharma pressure?
Business

Breast cancer drugs: Is UPA succumbing to US pharma pressure?

There has been a systematic effort by the western media, international business bodies and their trade proxies to malign India. Perhaps the biggest pressure came from the US, both by the government and trade and business organisations. <br /><br />

India revokes GSK patent on breast cancer drug Tykerb
Business

India revokes GSK patent on breast cancer drug Tykerb

India's patent appeals board has revoked a patent granted to GlaxoSmithKline Plc's breast cancer drug Tykerb, which is a salt form of the original compound, lapatinib.

How Big Pharma-designed cacophony against Ranbaxy drowns vital voices
Business

How Big Pharma-designed cacophony against Ranbaxy drowns vital voices

In the unresisted and rapidly rising cacophony against the FDA-tainted Ranbaxy, what get drowned unfortunately are voices that are vital to the country's drug industry and people's health.

Ranbaxy debacle: Big Pharma's target is Indian drug industry
Business

Ranbaxy debacle: Big Pharma's target is Indian drug industry

It's abundantly clear that the Ranbaxy fiasco in the US, in which the company has to pay $500 million for allegedly selling adulterated drugs, is the big opportunity that the multinational drug companies have been waiting for to malign India.

India-EU FTA will imperil lives, local industry, say activists
Economy

India-EU FTA will imperil lives, local industry, say activists

Holding placards that said: "EU FTA kills patients", "FTA kills domestic production of medicine" about 250 people gathered at Jantar Mantar this afternoon urging the government to not sign the Free Trade Agreement with the European Union

HC denies interim relief to Merck in patent case against Glenmark
Business

HC denies interim relief to Merck in patent case against Glenmark

The interim application of the multinational pharma major that Glenmark be restrained from manufacturing and selling the anti-diabetes medicines on the grounds that the salt used in the drugs were not of generic nature was denied by the court.<br /><br />

US trade office reviewing SC ruling against Novartis
Economy

US trade office reviewing SC ruling against Novartis

The United States is considering its response to the Supreme Court ruling against Novartis, which US drug manufacturers warn is the latest sign of a "deteriorating" environment for intellectual property rights in India.

Novartis patent blow: Why Big Pharma can't quit India
Business

Novartis patent blow: Why Big Pharma can't quit India

Much of the new business will still come from cheap generics made by local companies, but Western firms are also seeking to put their brands on unpatented medicines, prompting the likes of Abbott Laboratories and Daiichi Sankyo to buy up Indian companies.

Novartis judgment: Let's make research a priority, rest will follow
Business

Novartis judgment: Let's make research a priority, rest will follow

Our academic and research institutions have to make research a priority and the government has to liberally fund them. The bottomline of the Glivec and recent experiences is simple - we should get our priorities right. The rest will fall in place. <br /><br />

Drug R&D: Why India can easily ignore Novartis blackmail
Business

Drug R&D: Why India can easily ignore Novartis blackmail

India is a country where pharma companies can do research and development at lower cost. Ignoring this fact will be detrimental for the Big Pharma.

India rejects AstraZeneca's patent protection plea on cancer drug
Business

India rejects AstraZeneca's patent protection plea on cancer drug

<br /><br /> The decision is a setback for struggling AstraZeneca, which is battling to turn itself around as key drugs lose patent protection.